Cat. No.: DAB-0011700
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu50 of human AHCYL1/IRBIT protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | AHCYL1 |
| UniProt No. | O43865 |
| Gene ID | 10768 |
| Gene Description | S-adenosylhomocysteine hydrolase-like protein 1 is a member of S-adenosylhomocysteine hydrolase family, which participates in the metabolism of S-adenosyl-L-homocysteine. Two Drosophila homologs of S-adenosylhomocysteine hydrolase-like proteins, dAhcyL1 and dAhcyL2, were identified as novel components of methionine metabolism. dAhcyL1 and dAhcyL2 function as dominant-negative regulators of S-adenosylhomocysteine hydrolase. Global down-regulation of both dAhcyL1 and dAhcyL2 extended life span. In addition, brain-specific down regulation of dAhcyL1 extended life span. AHCYL1 is also known as inositol 1, 4, 5-trisphosphate receptor binding protein released with IP3. This protein binds to the endoplasmic reticulum calcium release channel IP3R and represses its acitivity. As a multifunctional regulator, AHCYL1/IRBIT can also form a complex with and suppress the activity of ribonucleotide reductase, thereby influencing the balance of deoxynucleotide triphosphates essential for DNA replication and genomic integrity. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
